Biotechnology News 13 November 2025

Nuvation Bio (NUVB) Stock Soars ~50% Today as B. Riley Starts Coverage With $12 Target – 19 November 2025

NEW YORK, November 19, 2025 – Shares of Nuvation Bio Inc. (NYSE: NUVB) exploded higher on Wednesday after B. Riley Securities initiated coverage with a bullish rating and a $12 price target, adding fresh fuel to a rally driven by

19 November 2025

Biotechnology·Financial Updates·Investment News·Stock Market

Can-Fite BioPharma (CANF) Soars on 9-Year Liver Cancer Survival Breakthrough with Namodenoson – November 18, 2025

Small-cap Israeli biotech rallies after reporting a decade-long cancer‑free outcome in advanced hepatocellular carcinoma and launching enrollment in a pivotal Phase III trial. Shares of Can-Fite BioPharma Ltd. (NYSE American: CANF, TASE: CANF) jumped on Tuesday after the company reported

18 November 2025

Biotechnology·Cancer Research·Pharmaceutical News·Stock Market

Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Why OLMA Stock Is Exploding Today Olema Pharmaceuticals didn’t publish a press release or file anything with the SEC this morning. Yet, its stock rocketed nearly threefold in pre‑market trading on Tuesday, November 18, 2025. TipRanks The real catalyst comes

18 November 2025

Biotechnology·Cancer Research·Investor News·Pharmaceuticals·Stock Market

Annovis Bio (ANVS) Soars After New Parkinson’s Biomarker Data Show Buntanetap Halts Cognitive Decline – November 17, 2025

On November 17, 2025, Annovis Bio, Inc. (NYSE: ANVS) released new Phase 3 data in early Parkinson’s disease showing that its lead drug candidate buntanetap halted cognitive decline and improved key Alzheimer’s-related biomarkers in a significant subset of patients. Annovis

17 November 2025

Biotechnology·Clinical Trials

Applied Therapeutics (APLT) Stock Explodes on Heavy Volume as FDA Scrutiny and Cash Concerns Collide – November 17, 2025

Applied Therapeutics Inc. (NASDAQ: APLT) is back on traders’ radar today, with its penny stock surging on enormous volume despite intense regulatory uncertainty and a stretched balance sheet. On November 17, 2025, APLT is trading like a biotech rollercoaster: pre‑market

17 November 2025

Biotechnology·Financial Analysis·Market News·Stocks

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Pfizer’s acquisition of Metsera, Inc. (formerly NASDAQ: MTSR) is now effectively complete, Metsera’s stock has been delisted, major index providers are removing the name, and antitrust scholars are using the failed Novo Nordisk bid as a case study in “attempted

17 November 2025

Biotechnology·Healthcare Industry·Mergers & Acquisitions·Pharma News

Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

As of this afternoon, Galmed Pharmaceuticals shares were changing hands around $1.18, up roughly 13% on the day, with more than 41 million shares traded—massively above the stock’s usual daily volume. TipRanks What Galmed Announced Today From its headquarters in

17 November 2025

Biotechnology·Cancer Research·Investment News·Pharmaceuticals·Stock Market

Autonomix Medical (AMIX) Stock Doubles on New Pancreatic Cancer Quality‑of‑Life Data – November 17, 2025 Update

All of today’s Autonomix (AMIX) news in one glance – 17 November 2025 As of this afternoon on November 17, 2025, all company‑specific news about Autonomix Medical, Inc. (NASDAQ: AMIX) centers on the same core development: new quality‑of‑life data from

17 November 2025

Biotechnology·Cancer Research·Investment Analysis·Stock Market

Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

What Zymeworks Announced Today Before the U.S. market open on November 17, 2025, Vancouver‑based Zymeworks Inc. (ZYME) released topline Phase 3 data from its pivotal HERIZON‑GEA‑01 study, evaluating Ziihera (zanidatamab‑hrii) in first‑line treatment of HER2‑positive locally advanced or metastatic gastroesophageal

17 November 2025

Biotechnology·Cancer Research·Clinical Trials·Healthcare News·Stock Market

Precigen (PGEN) Soars as PAPZIMEOS Launch, Q3 2025 Earnings and Fresh Analyst Upgrades Ignite Investor Interest

On 14 November 2025, Precigen, Inc. (NASDAQ: PGEN) is back in the spotlight. The gene‑therapy specialist’s stock is trading roughly 25–30% higher intraday around $4.90–$5.00, after closing at $3.86 on 13 November, on surging volume of nearly 11 million shares.

14 November 2025

Analyst Ratings·Biotechnology·Earnings Reports·Investment News·Stock Market

Scholar Rock (NASDAQ: SRRK) Soars on FDA Progress, $200M ATM and Q3 2025 Earnings – November 14, 2025 Update

Scholar Rock Holding Corporation (NASDAQ: SRRK) is back in the spotlight as its stock jumps more than 25% on the day after a pivotal FDA meeting, fresh Q3 2025 financial results, and the launch of a new $200 million at-the-market

14 November 2025

Biotechnology·Earnings Reports·FDA Updates·Pharmaceutical Industry·Stock Market

Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Vancouver / Jerusalem – November 13, 2025 – Shares of Clearmind Medicine Inc. (NASDAQ: CMND), a clinical‑stage psychedelic and neuroplastogen biotech company, jumped sharply on Thursday after the firm announced final approval to expand its FDA‑regulated Phase 1/2a clinical trial

13 November 2025

Biotechnology·Clinical Trials·Healthcare·Investment News·Stock Market

Biotechnology News 13 November 2025 - 19 November 2025